Robert Buynak

Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study

Robert Buynak, Douglas Y. Shapiro, Akiko Okamoto et al. · Expert Opinion on Pharmacotherapy · 2010 · 250 citations

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study

Nizar El-Khalili, Mark Joyce, Sarah Atkinson et al. · The International Journal of Neuropsychopharmacology · 2010 · 178 citations · Full text

Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial

Robert Buynak, Stephen A. Rappaport, Kevin Rod et al. · Clinical Therapeutics · 2015 · 43 citations

Pain Therapy, Open-label Extension Trial, Health Sciences +11

Interferon‐free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: <scp>SOUND</scp>‐C3, a Phase 2b study

Stefan Zeuzem, Jean‐François Dufour, Robert Buynak et al. · Liver International · 2014 · 21 citations

2006 GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN SIGNIFICANTLY IMPROVES VIROLOGIC RESPONSE AND ALT NORMALIZATION AT END-OF-TREATMENT AND IMPROVES SVR24 COMPARED TO PEG-IFN/RIBAVIRIN IN GENOTYPE-1 CHRONIC HCV PATIENTS

Ira M. Jacobson, John G. McHutchison, Thomas Boyer et al. · Journal of Hepatology · 2010 · 13 citations

Vaccination, Vaccine Development, Viral Hepatitis +7